CSBIO(SZ:300255) Nan Fang Du Shi Bao·2026-01-12 08:13Core Viewpoint - The article discusses a case of commercial bribery involving Shanghai Haiyilai Enterprise Consulting Management Partnership and Shanghai Hongjian Pharmaceutical Co., highlighting the unethical practices in pharmaceutical marketing and the regulatory response to such actions [1][2][3]. Group 1: Case Details - In January 2023, Shanghai Haiyilai signed a one-year information service agreement with Hongjian Pharmaceutical to promote the drug "Dahansuan Sodium Injection" in Shanghai [1]. - The company promised to increase the sales of the drug in exchange for bribes paid to doctors for prescribing the medication [1][2]. - A total of 35,046 yuan was paid in bribes to a doctor who prescribed 18,275 units of the drug during the year [2]. Group 2: Regulatory Actions - The Shanghai Putuo District Market Supervision Administration issued an administrative penalty of 300,000 yuan to the company for violating the Anti-Unfair Competition Law [2]. - The case illustrates the broader issue of pharmaceutical commercial bribery, which distorts fair competition and increases healthcare costs [3]. - The National Medical Insurance Administration has implemented a credit evaluation system to penalize companies involved in bribery and unfair practices [3]. Group 3: Industry Implications - The article emphasizes that pharmaceutical commercial bribery undermines the integrity of medical practices and leads to inflated drug prices, harming patients and healthcare funds [3]. - The Shanghai Drug Administration is initiating credit evaluations for involved companies, including the production company Hebei Changshan Biochemical Pharmaceutical Co., to address these unethical practices [4].